LT3204378T - N-piridinilo acetamido dariniai kaip wnt signalinio kelio inhibitoriai - Google Patents

N-piridinilo acetamido dariniai kaip wnt signalinio kelio inhibitoriai

Info

Publication number
LT3204378T
LT3204378T LT15782041T LT15782041T LT3204378T LT 3204378 T LT3204378 T LT 3204378T LT 15782041 T LT15782041 T LT 15782041T LT 15782041 T LT15782041 T LT 15782041T LT 3204378 T LT3204378 T LT 3204378T
Authority
LT
Lithuania
Prior art keywords
inhibitors
wnt signal
signal road
acetamide derivatives
pyridinyl
Prior art date
Application number
LT15782041T
Other languages
English (en)
Inventor
Inder Bhamra
Matilda Bingham
Richard Testar
Louise Sargent
Craig Donoghue
Original Assignee
Redx Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1417829.7A external-priority patent/GB201417829D0/en
Priority claimed from GBGB1511387.1A external-priority patent/GB201511387D0/en
Application filed by Redx Pharma Plc filed Critical Redx Pharma Plc
Publication of LT3204378T publication Critical patent/LT3204378T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
LT15782041T 2014-10-08 2015-10-08 N-piridinilo acetamido dariniai kaip wnt signalinio kelio inhibitoriai LT3204378T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1417829.7A GB201417829D0 (en) 2014-10-08 2014-10-08 Compounds
GBGB1511387.1A GB201511387D0 (en) 2015-06-29 2015-06-29 Compounds
PCT/GB2015/052939 WO2016055786A1 (en) 2014-10-08 2015-10-08 N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway

Publications (1)

Publication Number Publication Date
LT3204378T true LT3204378T (lt) 2019-10-25

Family

ID=54337304

Family Applications (1)

Application Number Title Priority Date Filing Date
LT15782041T LT3204378T (lt) 2014-10-08 2015-10-08 N-piridinilo acetamido dariniai kaip wnt signalinio kelio inhibitoriai

Country Status (24)

Country Link
US (4) US10047079B2 (lt)
EP (1) EP3204378B3 (lt)
JP (2) JP6722178B2 (lt)
KR (1) KR102525131B1 (lt)
CN (1) CN107108565B (lt)
AU (1) AU2015329784C1 (lt)
CA (1) CA2960446C (lt)
CY (1) CY1122243T1 (lt)
DK (1) DK3204378T6 (lt)
EA (1) EA034822B9 (lt)
ES (1) ES2754349T7 (lt)
HR (1) HRP20191826T4 (lt)
HU (1) HUE046914T2 (lt)
IL (1) IL251131B (lt)
LT (1) LT3204378T (lt)
MX (1) MX373651B (lt)
PH (1) PH12017500611A1 (lt)
PL (1) PL3204378T6 (lt)
PT (1) PT3204378T (lt)
SG (1) SG11201701837UA (lt)
SI (1) SI3204378T1 (lt)
SM (1) SMT201900615T1 (lt)
WO (1) WO2016055786A1 (lt)
ZA (1) ZA201701842B (lt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016055790A1 (en) 2014-10-08 2016-04-14 Redx Pharma Plc N-pyridinyl acetamide derivatives as wnt signalling pathway inhibitors
HUE046914T2 (hu) 2014-10-08 2020-04-28 Redx Pharma Plc N-piridinil-acetamid-származékok, mint a WNT jelátviteli út inhibitorai
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
US10793544B2 (en) 2016-09-01 2020-10-06 The Board Of Regents Of The University Of Texas System Disubstituted and trisubstituted 1,2,3-triazoles as Wnt inhibitors
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
JP2019064975A (ja) * 2017-10-03 2019-04-25 国立大学法人 熊本大学 抗がん剤
WO2019106146A1 (en) 2017-11-30 2019-06-06 Step Pharma S.A.S. Compounds
EP3717459B1 (en) * 2017-11-30 2026-01-21 Step Pharma S.A.S. Compounds
WO2019148244A1 (en) * 2018-02-01 2019-08-08 The University Of Sydney Anti-cancer compounds
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
US10961534B2 (en) 2018-07-13 2021-03-30 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating porphyria
ES3044436T3 (en) 2019-06-04 2025-11-26 Step Pharma S A S N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(ethylsulfonamido)pyrimidin-4-yl)tetrahydro-2h-pyran-4-carboxamide as a human ctps1 inhibitor for the treatment of proliferative diseases
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
AU2020407664A1 (en) 2019-12-20 2022-08-18 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
WO2022094477A1 (en) * 2020-11-02 2022-05-05 Icahn School Of Medicine At Mount Sinai Methods of treating tumors and cancers having dysregulated wnt signaling pathways
GB202100526D0 (en) 2021-01-15 2021-03-03 Redx Pharma Plc Pharmaceutical formulation
AU2022270657A1 (en) 2021-05-04 2023-11-16 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
IL316201A (en) 2022-04-08 2024-12-01 Eikonizo Therapeutics Inc Oxadiazole HDAC6 inhibitors and their uses
WO2024140653A1 (zh) * 2022-12-27 2024-07-04 南京圣和药业股份有限公司 选择性cdk12/13抑制剂及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1246847A (zh) 1996-12-23 2000-03-08 杜邦药品公司 作为Xa因子抑制剂的含氮杂芳族化合物
CA2276034A1 (en) 1996-12-23 1998-07-02 Mimi Lifen Quan Oxygen or sulfur containing 5-membered heteroaromatics as factor xa inhibitors
GB0226583D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
SE0203654D0 (sv) 2002-12-09 2002-12-09 Astrazeneca Ab New compounds
JP2006518738A (ja) * 2003-02-12 2006-08-17 トランス　テック　ファーマ，インコーポレイテッド 治療薬としての置換アゾール誘導体
JP2008515961A (ja) 2004-10-12 2008-05-15 アストラゼネカ アクチボラグ 癌に対する使用のためのキナゾリン誘導体
WO2008137408A1 (en) * 2007-04-30 2008-11-13 Genentech, Inc. Pyrazole inhibitors of wnt signaling
AU2008335709A1 (en) 2007-12-13 2009-06-18 Amgen Inc. Gamma secretase modulators
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
JP2014506568A (ja) * 2011-01-28 2014-03-17 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ Ｗｎｔ組成物およびその使用方法
EP2820151B1 (en) * 2012-02-28 2020-03-25 Novartis AG Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status
GB2513403A (en) 2013-04-26 2014-10-29 Agency Science Tech & Res WNT pathway modulators
HUE046914T2 (hu) 2014-10-08 2020-04-28 Redx Pharma Plc N-piridinil-acetamid-származékok, mint a WNT jelátviteli út inhibitorai
WO2016055790A1 (en) 2014-10-08 2016-04-14 Redx Pharma Plc N-pyridinyl acetamide derivatives as wnt signalling pathway inhibitors

Also Published As

Publication number Publication date
EA034822B1 (ru) 2020-03-25
MX373651B (es) 2020-03-31
SI3204378T1 (sl) 2019-12-31
US10047079B2 (en) 2018-08-14
NZ729820A (en) 2023-09-29
PL3204378T4 (pl) 2020-03-31
PT3204378T (pt) 2019-11-12
ZA201701842B (en) 2022-05-25
SMT201900615T1 (it) 2020-01-14
US20210046076A1 (en) 2021-02-18
CA2960446C (en) 2023-09-19
WO2016055786A1 (en) 2016-04-14
AU2015329784A1 (en) 2017-03-30
EP3204378B3 (en) 2022-05-25
PL3204378T3 (pl) 2020-03-31
IL251131B (en) 2020-07-30
ES2754349T7 (es) 2022-09-19
AU2015329784B2 (en) 2019-08-22
CA2960446A1 (en) 2016-04-14
ES2754349T3 (es) 2020-04-17
HRP20191826T4 (hr) 2022-08-05
HUE046914T2 (hu) 2020-04-28
MX2017004637A (es) 2017-06-30
JP2017530183A (ja) 2017-10-12
US12202826B2 (en) 2025-01-21
EA201790637A1 (ru) 2017-10-31
KR102525131B1 (ko) 2023-04-24
BR112017006476A2 (pt) 2017-12-19
SG11201701837UA (en) 2017-04-27
JP6722178B2 (ja) 2020-07-15
US20230365549A1 (en) 2023-11-16
US10793560B2 (en) 2020-10-06
EP3204378A1 (en) 2017-08-16
PH12017500611A1 (en) 2017-09-25
JP2020090542A (ja) 2020-06-11
DK3204378T6 (da) 2022-07-18
IL251131A0 (en) 2017-04-30
EA034822B9 (ru) 2020-10-23
EP3204378B1 (en) 2019-07-10
AU2015329784C1 (en) 2020-10-15
US20170275276A1 (en) 2017-09-28
US11643408B2 (en) 2023-05-09
CY1122243T1 (el) 2020-11-25
HRP20191826T1 (hr) 2020-01-10
KR20170063906A (ko) 2017-06-08
US20180319788A1 (en) 2018-11-08
PL3204378T6 (pl) 2022-09-12
DK3204378T3 (da) 2019-10-21
CN107108565A (zh) 2017-08-29
CN107108565B (zh) 2019-08-23

Similar Documents

Publication Publication Date Title
LT3204378T (lt) N-piridinilo acetamido dariniai kaip wnt signalinio kelio inhibitoriai
SG11201702142UA (en) N-pyridinyl acetamide derivatives as wnt signalling pathway inhibitors
HRP20181795T1 (hr) Biciklički heterociklilni derivati kao inhibitori irak4
HUE040434T2 (hu) Szelektív CDK4/6 inhibitor szilárd alakjai
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
HRP20181650T1 (hr) Biciklički heterociklički derivati kao inhibitori bromodomene
HUE053653T2 (hu) FGFR inhibitor és IGF1R inhibitor kombinációi
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
EP2956745A4 (en) NEW ROAD DETECTION LOGIC
HUE051925T2 (hu) Dizabiciklooktán származék kristályai és diazabiciklooktán származék kristályainak elõállítási eljárása
ME03360B (me) Mono- ili di-supsтituisani derivaтi indola као inhibiтori replikacije virusa denge
EP3386505A4 (en) AZA-BENZIMIDAZOLINHIBITORS OF PAD4
DK3446894T3 (da) Inspektion af køretøjsdæk
PT3457851T (pt) Derivados de sobetiroma
IL249674A0 (en) Quinolizinone derivatives as pi3k inhibitors
FR3023290B1 (fr) Derives de flavaglines
DK3204352T3 (da) Hæmmere af lysin-gingipain
HRP20181441T1 (hr) Inhibitori sintaze aldosterona
IL250613B (en) Substituted bicyclic compounds
EP3259250C0 (en) NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-ARNT SYNTHETASE INHIBITORS
EP2948557A4 (en) CLEANING OF CADAVERIN
HUE046994T2 (hu) Pirido-oxazinon származékok TNAP inhibitorokként
PL3237368T3 (pl) Sposób oczyszczania laktylanu
BR112017010588A2 (pt) formas cristalinas de inibidores de parp
TH1601002217A (th) กระบวนการสำหรับการเตรียมของสารยับยั้ง pde4